230 related articles for article (PubMed ID: 31209964)
1. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era.
Chiou FK; Beath SV; Patel M; Gupte GL
Pediatr Transplant; 2019 Sep; 23(6):e13519. PubMed ID: 31209964
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
[TBL] [Abstract][Full Text] [Related]
3. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
4. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
[TBL] [Abstract][Full Text] [Related]
5. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
Mizuhara K; Fujii N; Meguri Y; Takahashi T; Aoe M; Nakamura M; Seike K; Sando Y; Fujii K; Abe M; Sumii Y; Urata T; Fujiwara Y; Saeki K; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Maeda Y
Int J Hematol; 2020 Sep; 112(3):422-426. PubMed ID: 32342335
[TBL] [Abstract][Full Text] [Related]
6. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
9. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
[TBL] [Abstract][Full Text] [Related]
11. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
13. Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder.
Kinzel M; Kalra A; Khanolkar RA; Williamson TS; Li N; Khan F; Puckrin R; Duggan PR; Shafey M; Storek J
Transplant Cell Ther; 2023 Jan; 29(1):43.e1-43.e8. PubMed ID: 36273783
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
15. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
[TBL] [Abstract][Full Text] [Related]
16. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
[TBL] [Abstract][Full Text] [Related]
18. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.
Christou EAA; Giardino G; Worth A; Ladomenou F
Int Rev Immunol; 2017 Nov; 36(6):352-359. PubMed ID: 28800262
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; Capote FJ; Gómez-Codina J; Panizo C; Salar A; Sancho JM; López A; Briones J; Muñoz A; Encuentra M; Mercadal S; Domingo-Domenech E; de Sevilla AF;
Ann Hematol; 2021 Apr; 100(4):1023-1029. PubMed ID: 32367180
[TBL] [Abstract][Full Text] [Related]
20. Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.
Nakanishi C; Kawagishi N; Sekiguchi S; Akamatsu Y; Sato K; Miyagi S; Takeda I; Fukushima D; Kobayashi Y; Ishida K; Niizuma H; Tsuchiya S; Wada M; Nio M; Satomi S
Surg Today; 2012 Aug; 42(8):741-51. PubMed ID: 22278621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
